European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

November 30, 2018

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2023

Conditions
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Interventions
DRUG

Ganetespib

Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)

DRUG

Niraparib

Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)

DRUG

Carboplatin

In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)

DRUG

Paclitaxel

Paclitaxel dose will be 175mg/m² (q3w)

DRUG

Gemcitabine

Gemcitabine dose will be 1000mg/m² (q3w, d1 \& d8)

Trial Locations (13)

3000

UZLeuven, Leuven

6020

Medical University of Innsbruck, Innsbruck

10117

Universitätsmedizin Berlin Charité, Berlin

14076

Centre de lutte contre le cancer Francois Baclesse, Caen

20133

Fondazione IRCCS Istituto Nazionale dei tumori Milano, Milan

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

40138

Azienda Ospedaliero Bologna, Bologna

45136

Kliniken Essen Mitte, Evang. Huyssens- Stiftung/Knappschaft GmbH, Essen

53127

Universitätsklinikum Bonn, Bonn

69008

Centre anticancereux Leon Berard, Lyon

75004

Assistance Publique Hôpitaux de Paris, Paris

01069

Universitätsklinikum Dresden, Dresden

00168

Università Cattolica del Sacro Cuore, Rome

All Listed Sponsors
collaborator

European Commission

OTHER

lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT03783949 - European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | Biotech Hunter | Biotech Hunter